human tetanus immunoglobulin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human tetanus immunoglobulin: clinical details
Prescribing considerations
- Confirm wound classification, vaccination history and whether antibody production is severely impaired.
- Review previous reactions to immunoglobulins or blood products, IgA deficiency, bleeding disorders and thromboembolic risk factors.
- Ensure adequate hydration in patients at thrombotic risk and avoid intravascular administration.
- Administer any simultaneous tetanus vaccine at a separate anatomical site.
- Record the product name and batch number for traceability.
- Donor selection, donation screening and viral reduction measures reduce, but cannot eliminate, transmissible-agent risk.
Contraindications and cautions
- Hypersensitivity to human tetanus immunoglobulin or an excipient.
- Hypersensitivity to human immunoglobulins, particularly in patients with anti-IgA antibodies.
Monitoring
- Watch for hypersensitivity, hypotension or shock during and after administration.
- Advise patients about symptoms of arterial or venous thromboembolism requiring immediate assessment.
- Passively transferred antibodies may cause misleading serology, including some red-cell antibody tests.
Clinical pharmacology
A plasma-derived preparation composed mainly of IgG with a high content of antibodies against tetanus toxin. After intramuscular administration it enters the circulation after a delay; IgG is subsequently cleared through the reticuloendothelial system.
Formulation and product differences
- The selected product is a clear or slightly opalescent, colourless to pale-yellow solution for injection in a single-use vial. Potency varies by batch, and the label states the batch-specific concentration and administration volume.
- It contains a small amount of IgA and includes sodium chloride, glycine and sodium acetate among its excipients.
human tetanus immunoglobulin interactions
The main clinically relevant interaction is with certain vaccines.
Live attenuated viral vaccines, including measles, mumps, rubella and varicella vaccines
Transferred antibodies may reduce the immune response, so the vaccination team should plan timing.
Tetanus-containing vaccine
It may be given at the same attendance when indicated, but at a different injection site.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.